Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda

Questex's Fierce Life Sciences announced the agenda for the 16th annual PODD (Partnership Opportunities in Drug Delivery) Conference, scheduled for October 29-30, 2026, in Boston. The event will gather over 1,000 industry executives and features 150+ sessions with keynotes from Regeneron's Dr. George Yancopoulos and MIT's Dr. Robert Langer, covering topics including AI in drug delivery, pharma partnering strategies, and reimbursement challenges.

06/23/2026, 8:00 AM • GlobeNewswire

AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?

AbbVie announced a $10.9 billion acquisition of clinical-stage biotech Apogee Therapeutics, paying $135.11 per share in cash. The deal strengthens AbbVie's immunology portfolio with access to promising drug candidates like zumilokibart for eczema and asthma. While the acquisition will create near-term EPS headwinds, analysts expect it to be accretive by 2032 and support AbbVie's dividend yield of over 3%.

06/22/2026, 6:36 PM • The Motley Fool

Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

The article compares two emerging biotech stocks: Intellia Therapeutics, which focuses on CRISPR gene-editing technology with promising Phase III trial data but significant losses and clinical risks, and Omeros, which recently achieved FDA approval for Yartemlea and posted its first commercial revenue of $9.89 million. While Intellia offers higher upside potential, Omeros is deemed the safer choice due to its transition to profitability, strong initial sales, and healthier balance sheet, despite trading at a premium valuation.

06/20/2026, 11:02 AM • The Motley Fool

This Stock Is Up 58% This Year. Is It too Late to Buy?

Intellia Therapeutics' stock has surged 58% year-to-date following positive phase 3 trial results for lonvo-z, a gene-editing treatment for hereditary angioedema. While lonvo-z shows promise with an 87% reduction in attacks, its commercial opportunity is limited to a small patient population (~7,000 in the U.S.), potentially generating $3.5 billion in lifetime sales. The company's more promising pipeline candidate, nex-z for transthyretin amyloidosis, won't show results until 2027. Investors should weigh significant clinical and regulatory risks against potential upside.

06/17/2026, 2:30 AM • The Motley Fool

Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?

The article compares two biotech companies with different risk profiles: Ocular Therapeutix, which has commercial revenue from its Dextenza product and is preparing an FDA application for Axpaxli, versus Prime Medicine, which is developing early-stage Prime Editing gene therapy technology. Despite Prime Medicine's moonshot potential, Ocular Therapeutix is recommended as the better choice for average investors in 2026 due to its more advanced development stage and clearer investment thesis, though both remain high-risk biotech plays.

06/15/2026, 4:10 PM • The Motley Fool

Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Parabilis Medicines (NASDAQ: PBLS), a clinical-stage biopharmaceutical company, announced the successful closing of its upsized IPO on June 11, 2026, raising $770.5 million in gross proceeds from 38.5 million shares at $20 per share, plus an additional $75 million from a concurrent private placement with Regeneron Pharmaceuticals. The company has raised over $1.2 billion in total funding in 2026 to support development of its proprietary Helicons™ therapeutic platform targeting undruggable protein targets.

06/11/2026, 4:05 PM • Benzinga

Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight

The lupus nephritis drug development pipeline is rapidly expanding with 30+ pharmaceutical companies developing 35+ pipeline therapies across various clinical stages. Key players including Novartis, Simcere Pharmaceutical, Kyverna Therapeutics, Century Therapeutics, and Adicet Bio are advancing promising treatments with novel mechanisms of action such as BAFF-R inhibitors, CAR-NK cell therapies, and anti-CD19/CD20 approaches. Recent regulatory milestones include FDA RMAT designations for cell therapies and positive Phase III trial results, indicating accelerating progress in addressing this serious autoimmune kidney disease.

06/10/2026, 1:00 PM • GlobeNewswire

Parabilis Medicines Announces Pricing of Upsized Initial Public Offering

Parabilis Medicines, a clinical-stage biopharmaceutical company, announced the pricing of its upsized IPO at $20.00 per share for 33.5 million shares, expected to raise $670 million in gross proceeds. The company will also conduct a concurrent private placement with Regeneron Pharmaceuticals for 4.17 million shares at $18.00 per share, raising approximately $75 million. Trading on Nasdaq under ticker 'PBLS' is expected to begin June 10, 2026.

06/09/2026, 8:22 PM • Benzinga

Parabilis Medicines Announces Pricing of Upsized Initial Public Offering

Parabilis Medicines, a clinical-stage biopharmaceutical company, priced its IPO at $20 per share for 33.5 million shares, expected to raise $670 million in gross proceeds. The company will also receive approximately $75 million from a concurrent private placement with Regeneron Pharmaceuticals at $18 per share. Trading on Nasdaq under ticker PBLS is expected to begin June 10, 2026.

06/09/2026, 8:22 PM • GlobeNewswire

Treg Cell-Based Therapies Clinical Trial Pipeline Appears Robust With 29+ Key Pharma Companies Actively Working in the Domain | DelveInsight

The Treg cell-based therapies pipeline shows robust development with 29+ pharmaceutical companies actively working on 35+ therapies across various clinical stages. Key players including Orca Bio, Cellenkos, Quell Therapeutics, GentiBio, and others are advancing promising candidates like Orca-T and CK0801, with approximately 2+ therapies in late-stage development and 10+ in mid and early stages. Recent developments include FDA clearances and clinical trial initiations across multiple companies.

06/09/2026, 1:00 PM • GlobeNewswire

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

CytomX Therapeutics expanded its collaboration with Regeneron Pharmaceuticals to develop conditionally-activated bispecific cancer therapies combining CytomX's PROBODY platform with Regeneron's Veloci-Bi platform. CytomX will receive $37 million for two additional programs, with potential total milestones reaching approximately $4 billion across up to 6 additional future targets.

06/03/2026, 8:00 AM • GlobeNewswire

Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight

Over 25 pharmaceutical companies are advancing 30+ pipeline drugs for myasthenia gravis treatment, with approximately 5+ therapies in late-stage development. Key players including Immunovant, Cartesian Therapeutics, Novartis, and others are developing promising therapies using novel mechanisms of action such as IgG degraders and complement inhibitors. Recent developments include positive Phase III trial results and regulatory approvals for multiple candidates.

06/02/2026, 1:00 PM • GlobeNewswire

Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

The World Health Organization's Therapeutics Advisory Group has recommended maftivimab, a component of Regeneron's Inmazeb, for clinical trial evaluation against Bundibugyo ebolavirus following WHO's declaration of a public health emergency in the Democratic Republic of Congo and Uganda. Maftivimab has demonstrated broad in vitro activity against multiple Ebola species and has been safely administered to hundreds of patients as part of Inmazeb, which is already FDA-approved for Zaire ebolavirus treatment.

05/28/2026, 4:00 PM • GlobeNewswire

Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing

Rhenman & Partners Asset Management AB sold its entire 420,000-share stake in Vera Therapeutics (VERA) during Q1 2026, valued at approximately $18.1 million. The position, which represented 2.0% of the fund's assets in the prior quarter, was fully exited. Despite the sale, Vera Therapeutics stock has surged 81.4% over the past year and outperformed the S&P 500 by 55 percentage points.

05/26/2026, 2:29 PM • The Motley Fool

CytomX Therapeutics to Present at Upcoming June Investor Conferences

CytomX Therapeutics announced that management will participate in the Jefferies Global Healthcare Conference on June 4, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company will host fireside chats and one-on-one investor meetings at both events. CytomX is a clinical-stage biopharmaceutical company developing conditionally activated masked PROBODY therapeutics for oncology, with lead candidates including varsetatug masetecan (Varseta-M) for colorectal cancer and CX-801 for melanoma.

05/21/2026, 8:00 AM • GlobeNewswire